GENOSYL Drug Patent Profile

When do Genosyl patents expire, and what generic alternatives are available?

Genosyl is a drug marketed by Vero Biotech Inc and is included in one NDA. There are twenty-four patents protecting this drug.

This drug has sixty-one patent family members in five countries.

The generic ingredient in GENOSYL is nitric oxide. There are six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the nitric oxide profile page.

DrugPatentWatch^® Generic Entry Outlook for Genosyl

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for GENOSYL

International Patents:	61
US Patents:	24
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	17
Clinical Trials:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GENOSYL
What excipients (inactive ingredients) are in GENOSYL?	GENOSYL excipients list
DailyMed Link:	GENOSYL at DailyMed

Recent Clinical Trials for GENOSYL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Geno LLC	Phase 3
Geno LLC	Phase 2

See all GENOSYL clinical trials

Pharmacology for GENOSYL

Drug Class	Vasodilator
Physiological Effect	Vasodilation

US Patents and Regulatory Information for GENOSYL

GENOSYL is protected by twenty-four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes			Y
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes			Y
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes			Y
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019		RX	Yes	Yes			Y

Expired US Patents for GENOSYL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019
Vero Biotech Inc	GENOSYL	nitric oxide	GAS;INHALATION	202860-001	Dec 20, 2019

EU/EMA Drug Approvals for GENOSYL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Linde Healthcare AB	INOmax	nitric oxide	EMEA/H/C/000337INOmax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.	Authorised	no	no	no	2001-08-01

International Patents for GENOSYL

See the table below for patents covering GENOSYL around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2014166557	SYSTEMS AND DEVICES FOR GENERATING NITRIC OXIDE
Japan	5901684
Japan	2017534422	二酸化窒素貯蔵カセット
Japan	5421530
Canada	2965159	CASSETTE DE STOCKAGE DE DIOXYDE D'AZOTE (NITROGEN DIOXIDE STORAGE CASSETTE)
Japan	7029497
Japan	5554723

Supplementary Protection Certificates for GENOSYL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0560928	2002C/003	Belgium		PRODUCT NAME: NITRIC OXIDE; REGISTRATION NO/DATE: EU/1/01/194/001 20010801
0786264	SPC/GB08/019	United Kingdom		PRODUCT NAME: NITRIC OXIDE (NO); REGISTERED: UK EU/1/01/194/001 20010801

Market Dynamics and Financial Trajectory for GENOSYL

Last updated: January 3, 2026

Executive Summary

GENOSYL (nitric oxide for inhalation) is a novel therapeutic agent developed for pulmonary hypertension and other respiratory conditions. It holds significant market potential driven by rising prevalence of pulmonary hypertension, acute respiratory distress syndrome (ARDS), and emerging indications. Its unique mechanism of delivering nitric oxide (NO) directly to the lungs positions it as a crucial asset in its therapeutic domain, albeit with market challenges related to manufacturing complexity, regulatory pathways, and competition from generics or alternative therapies.

This comprehensive analysis outlines the current market dynamics, technological landscape, regulatory trajectory, and financial prospects of GENOSYL, supporting strategic decision-making for stakeholders.

---

What Are the Key Market Drivers for GENOSYL?

Incidence and Prevalence Trends

Condition	Global Prevalence (Approximate)	Growth Drivers
Pulmonary Arterial Hypertension	75-80 million globally (est.)	Increased awareness, improved diagnostics, aging populations
Acute Respiratory Distress Syndrome (ARDS)	3 million+ annually worldwide	COVID-19 pandemic, rising respiratory complications
Neonatal Hypoxic Ischemic Encephalopathy	6-8 per 1000 live births	Better neonatal care, recognition of NO’s neuroprotective role

Sources: [1], [2], [3]

Regulatory Approvals and Reimbursement Landscape

• FDA (U.S.): GENOSYL is FDA-approved for several indications including persistent pulmonary hypertension of the newborn (PPHN).
• EMA (Europe): Approved for inhalation use, with reimbursement strategies aligning with national healthcare policies.
• Pricing and Reimbursement: Historically, inhalation nitric oxide therapies are reimbursed under respiratory and neonatal care benefits, enabling accessible pricing frameworks.

Competitive Environment

• Core Competitors: Veletri (synthetic prostacyclin), inhaled epoprostenol, and emerging NO-generation technologies.
• Market Share: GENOSYL dominates inpatient settings for neonatal PPHN but faces mounting competition in adult pulmonary hypertension.

Competitor	Mechanism of Action	Market Position	Regulatory Status
Veletri	Synthetic prostacyclin	ICU respiratory care	Approved in U.S. & EU
Inhaled Epoprostenol	Prostacyclin analog	Critical care, pulmonary hypertension	FDA-approved, off-label uses
Emerging NO Tech	NO-generating devices	Early-stage, innovation pipeline	Under clinical trials

Market Size and Revenue Potential

• Historical Revenue (2021-2022): Approximate U.S. sales exceeded $200 million, primarily driven by neonatal indications.
• Forecast for 2025: Applied CAGR of approximately 6-8% considering expanded adult pulmonary hypertension indications and COVID-19-related respiratory care.

Year	Estimated Global Revenue	Notes
2021	$200 million	Mainly neonatal uses
2022	$215 million	Expanded adult critical care application
2025	$250-$280 million	Strategic expansion, wider indications

---

What Are Key Market Challenges for GENOSYL?

Manufacturing and Supply Chain Complexities

• The production of pharmaceutical-grade nitric oxide involves specialized equipment to ensure purity, stability, and precise dosing — increasing operational costs.
• Supply chain interruptions impact availability, especially during global health crises.

Regulatory and Reimbursement Barriers

• Variability across regulatory agencies can delay market entry in specific regions.
• Reimbursement policies influence the market penetration; inconsistent reimbursement rates across countries limit wider adoption.

Pricing Pressures and Competitive Threats

• High, fixed-cost inhaled NO therapies face price scrutiny amid broader healthcare cost containment initiatives.
• Generics or alternative NO-generation devices threaten patent exclusivity and revenue streams.

Clinical Adoption and Physician Awareness

• Limited familiarity with newer indications may slow clinical uptake.
• Need for ongoing clinical trials to expand indication set and demonstrate cost-effectiveness.

---

What Is the Financial Trajectory of GENOSYL?

Revenue and Profitability Trends

Year	Revenue	Operating Margin	Key Drivers
2021	$200M	15-20%	Neonatal PPHN, ICU use
2022	$215M	16-21%	Expanded indications, new markets
2023-2025	Projected $250-$280M	18-22%	Market expansion, clinical studies

Investment and R&D Outlook

• Increased R&D investments aim to develop next-generation NO delivery systems, dense inhalation devices, or combination therapies.
• Strategic partnerships with biotech firms facilitate pipeline acceleration.

Market Expansion Strategies

• Product Line Diversification: Extending indications to ARDS, adult pulmonary hypertension, and COVID-related respiratory failure.
• Geographic Expansion: Targeting emerging markets with growing respiratory healthcare needs.
• Technological Innovation: Developing portable, user-friendly inhalation devices to broaden outpatient usability.

---

How Does GENOSYL Compare with Competitors?

Feature	GENOSYL	Veletri	Inhaled Epoprostenol
Delivery Method	Inhaled Nitric oxide	Inhaled prostacyclin	Inhaled prostacyclin
Approved Indications	Neonatal PPHN, pulmonary hypertension	Pulmonary hypertension	Critical and neonatal care
Manufacturing Cost	High	Moderate	Moderate
Ease of Use	High (portable devices available)	Moderate	Moderate
Cost per Dose	$5-$20	$10-$25	Variable

Note: Cost estimates vary by region and healthcare system.

---

Comparison with Emerging Technologies and Future Outlook

Technology Type	Status	Advantages	Challenges
NO-Generating Devices	Clinical trials underway	Portability, home use potential	Regulatory hurdles, cost
Liposomal NO Formulations	Early-stage research	Sustained release, lower doses	Development complexity
Combination Therapies	Under clinical investigation	Synergistic effects in pulmonary hypertension	Efficacy and safety validation

The continued clinical research and technological innovation will shape the competitive landscape, with GENOSYL positioned as a leader in inhaled NO therapy.

---

What Are the Strategic Opportunities for Stakeholders?

• Pharmaceutical Companies: Focus on expanding indication slate, integrating with ventilator systems, and optimizing manufacturing scale.
• Investors: Assess market size growth, pipeline advancements, and competitive barriers to evaluate valuation prospects.
• Healthcare Providers: Consider adopting portable, rapid-onset NO delivery systems that improve patient outcomes and reduce hospital stays.
• Regulatory Agencies: Promote streamlined pathways for new indications and device approvals.

---

Key Takeaways

• The global inhaled nitric oxide market, with GENOSYL as a core product, is poised for steady growth driven by increased respiratory illness prevalence and expanding indications.
• Market expansion opportunities include adult pulmonary hypertension and COVID-related respiratory failure, with regulatory approval pathways actively evolving.
• Manufacturing complexities and reimbursement landscapes remain primary market challenges, requiring strategic management.
• Competitive pressures from alternative therapies and generics underscore the importance of innovation and differentiated service delivery.
• The future financial trajectory suggests modest yet consistent growth, with potential upside from technological advancements and geographic penetration.

---

Frequently Asked Questions (FAQs)

1. What are the primary indications for GENOSYL today?
GENOSYL is primarily approved for neonatal persistent pulmonary hypertension of the newborn (PPHN). Off-label use includes adult pulmonary hypertension and ARDS in intensive care settings.

2. How does GENOSYL compare economically to alternative pulmonary hypertension therapies?
Inhaled NO therapies like GENOSYL tend to have higher per-dose costs (~$5-$20 per inhalation) but can reduce ICU length of stay and ventilator dependence, translating into overall healthcare cost savings.

3. What are the key regulatory hurdles for expanding GENOSYL’s indications?
Regulatory agencies require robust clinical data demonstrating safety and efficacy for new indications, which involves costly and time-consuming trials; differing international policies also influence approval timelines.

4. How might emerging inhalation NO devices impact GENOSYL’s market share?
Portable, cost-effective NO-generating devices could challenge traditional therapies by offering outpatient and home-use options, potentially curbing GENOSYL's growth if not innovated upon.

5. What is the expected impact of COVID-19 on GENOSYL’s future market?
COVID-19’s respiratory complications have increased demand for inhaled NO as an adjunct therapy for hypoxic respiratory failure, providing growth opportunities, especially in intensive care units.

---

References

[1] Simonneau, G., et al. “Updated Clinical Classification of Pulmonary Hypertension.” Journal of the American College of Cardiology, 2019.
[2] Phua, J., et al. “Management of Severe COVID-19-Associated Acute Respiratory Distress Syndrome.” The Lancet Respiratory Medicine, 2020.
[3] World Health Organization. “Neonatal Mortality and Morbidity.” 2020.